"Lamivudine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A reverse transcriptase inhibitor and ZALCITABINE analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat HIV disease.
| Descriptor ID |
D019259
|
| MeSH Number(s) |
D03.383.742.680.245.500.950.500 D13.570.230.329.950.500 D13.570.230.500.925.500 D13.570.685.245.500.950.500
|
| Concept/Terms |
Lamivudine- Lamivudine
- 3TC
- 2',3'-Dideoxy-3'-thiacytidine
- 2',3' Dideoxy 3' thiacytidine
|
Below are MeSH descriptors whose meaning is more general than "Lamivudine".
Below are MeSH descriptors whose meaning is more specific than "Lamivudine".
This graph shows the total number of publications written about "Lamivudine" by people in this website by year, and whether "Lamivudine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 1999 | 1 | 1 | 2 |
| 2000 | 1 | 6 | 7 |
| 2002 | 0 | 1 | 1 |
| 2003 | 1 | 1 | 2 |
| 2007 | 0 | 1 | 1 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Lamivudine" by people in Profiles.
-
An Efficient Humanized Mouse Model for Oral Anti-Retroviral Administration. Cells. 2023 03 28; 12(7).
-
Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA <500?000 copies/mL: week 48 outcomes from ACTG 5353. J Antimicrob Chemother. 2019 05 01; 74(5):1376-1380.
-
ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected Participants With HIV-1 RNA <500000 Copies/mL. Clin Infect Dis. 2018 05 17; 66(11):1689-1697.
-
Evidence of ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of lopinavir-ritonavir treatment. Clin Infect Dis. 2007 Mar 01; 44(5):749-54.
-
Triple-nucleoside analog antiretroviral therapy: is there still a role in clinical practice? A review. MedGenMed. 2005 Jun 02; 7(2):70.
-
Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study. AIDS. 2004 Mar 26; 18(5):775-9.
-
Resistance of HBV to adefovir dipivoxil: a case for combination antiviral therapy? Hepatology. 2003 Dec; 38(6):1584-7.
-
MDR1 gene polymorphisms and phase 1 viral decay during HIV-1 infection: an adult AIDS Clinical Trials Group study. J Acquir Immune Defic Syndr. 2003 Nov 01; 34(3):295-8.
-
Impact of anti-hepatitis Bc-positive grafts on the outcome of liver transplantation for HBV-related cirrhosis. Transplantation. 2002 May 27; 73(10):1598-602.
-
Evidence of immune reconstitution in antiretroviral drug-experienced patients with advanced HIV disease. AIDS Res Hum Retroviruses. 2002 Jan 20; 18(2):95-102.